Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL150661 | 0.77 | NQO1 (0.33) | ERN1 | |
| SCHEMBL28013945 | 0.73 | ERN1 (0.34) | ERN1 | |
| SCHEMBL27470302 | 0.71 | ERN1 (0.35) | ERN1 | |
| SCHEMBL21354550 | 0.70 | TRPA1 (0.33) | HPGDHTTERN1 | |
| SCHEMBL28982574 | 0.70 | ERN1 (0.36) | ERN1 | |
| SCHEMBL23797890 | 0.69 | HSPD1 (0.34) | ALDH1A1ERN1 | |
| SCHEMBL3285717 | 0.65 | — | — | |
| SCHEMBL3997148 | 0.61 | — | — | |
| SCHEMBL3232626 | 0.60 | EPHX2 (0.62) | ALDH1A1HTTNPSR1 | |
| SCHEMBL25375943 | 0.60 | TACR1 (0.40) | ALDH1A1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3715346-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2024-01-03 | — | — | EP | claimed |
| EP-3092220-B1 | VITAMIN C PRODRUGS AND USES THEREOF | UNIV FLORIDA (US) | 2021-01-20 | — | — | EP | claimed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | claimed |
| EP-2016044-B1 | PENTACYCLINE DERIVATIVES FOR THE TREATMENT OF INFECTIONS | HARVARD COLLEGE (US) | 2020-06-10 | — | — | EP | claimed |
| EP-3209648-B1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA FARBER CANCER INST INC (US) | 2020-03-11 | — | — | EP | claimed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-115322193-A | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-11-11 | — | — | CN | disclosed |
| CN-111099941-B | Preparation method of alkyl nitrile compound | 中国科学院上海有机化学研究所 | 2022-10-18 | — | — | CN | disclosed |
| CN-115135765-A | Chemically modified oligonucleotides targeting bromodomain-containing protein 4(BRD4) for immunotherapy | 菲奥医药公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-111032655-B | EGFR and/or HER2 inhibitors and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-109563509-B | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNAs | 菲奥医药公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114751920-A | Antitumor compounds | 法马马有限公司 | 2022-07-15 | — | — | CN | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | ALDH1A1 3310/4885MAPT 3854/4885HPGD 865/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | ALDH1A1 319/4885MAPT 347/4885HPGD 666/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | ALDH1A1 319/4885MAPT 347/4885HPGD 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.